Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)

The McGill Pain Questionnaire: Major properties and scoring methods

Ronald Melzack · Pain · 1975 · 6.9K citations

Nursing, Psychology, Pain Management +15

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Medicine, Oncology, Urology +12

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +17

Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer

F. Saad, D. M. Gleason, R. Murray et al. · JNCI Journal of the National Cancer Institute · 2004 · 1.2K citations

Medicine, Pharmacology, Pharmacotherapy +14